Article Sidebar

PDF (Tiếng Việt)
Published: 2026-03-09
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v199i2.4682
Issue
Vol. 199 No. 2 (2026)
Section
Các bài báo
How to Cite
Anh, H. P., Hạnh, C. H., Ngà, N. T., Hoa, H. T., Băng, Đặng T. C., & Lê, N. N. Q. (2026). Foscarnet desensitization for treatment of Cytomegalovirus in a child with drug allergy post stem cell transplantation: A rare case report summary. Journal of Medical Research, 199(2), 761-768. https://doi.org/10.52852/tcncyh.v199i2.4682

Foscarnet desensitization for treatment of Cytomegalovirus in a child with drug allergy post stem cell transplantation: A rare case report summary

Ha Phuong Anh, Chu Hong Hanh, Nguyen Thi Nga, Ha Thi Hoa, Dang Thi Cam Bang, Nguyen Ngoc Quynh Le

Main Article Content

Abstract

Cytomegalovirus (CMV) is a life-threatening opportunistic infection in patients undergoing allogeneic hematopoietic stem cell transplantation. Foscarnet is an effective antiviral agent against CMV; however, hypersensitivity reactions may limit its use. We report a child diagnosed with Wiskott- Aldrich syndrome who underwent stem cell transplantation. During transplantation, the child developed CMV infection that did not respond to conventional treatment, therefore intravenous foscarnet was prescribed. However, the child experienced anaphylaxis. Due to lack of suitable alternative therapy, intravenous foscarnet desensitization was performed. The desensitization protocol was successfully completed under close monitoring. The 22-step desensitization protocol was performed safely, tolerated well, the stem cell transplantation was successful, and CMV was controlled, with no recurrence of the allergic reaction. Foscarnet desensitization is a viable and effective option for treating CMV infection in patients with drug hypersensitivity reactions.

Article Details

Keywords

Cytomegalovirus, stem cell transplantation, drug hypersensitivity, foscarnet, drug desensitization

References

1. Ljungman P. The role of cytomegalovirus serostatus on outcome of hematopoietic stem cell transplantation. Curr Opin Hematol. 2014; 21(6): 466-469. doi:10.1097/MOH.0000000000000085.
2. Metafuni E, Chiusolo P, Sica S, et al. Foscarnet treatment of cytomegalovirus infection in haploidentical or unrelated donor transplants. Bone Marrow Transplant. 2018; 53(12): 1560-1567. doi:10.1038/s41409-018-0200-y.
3. Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials. Clin Infect Dis. 2017; 64(1): 87-91. doi:10.1093/cid/ciw668.
4. Kang SY, Seo J, Kang HR. Desensitization for the prevention of drug hypersensitivity reactions. Korean J Intern Med. 2022; 37(2): 261-270. doi:10.3904/kjim.2021.438.
5. Castells M. Rapid desensitization for hypersensitivity reactions to medications. Immunol Allergy Clin North Am. 2009; 29(3): 585-606. doi:10.1016/j.iac.2009.04.012.
6. Boyacıoğlu Ö. K., Asilsoy S., Atay Ö., Al S. Successful intravenous foscarnet desensitization. Cukurova Med J. 2022; 47(4): 1787-1789. DOI: 10.17826/cumj.1164257.
7. Thúy N.T.D., Thuyết L.T. Nghiên cứu đặc điểm dị ứng kháng sinh nặng ở trẻ em năm 2014 - 2016 tại Khoa Miễn dịch Dị ứng - Bệnh viện Nhi Trung ương. Journal of 108 - Clinical Medicine and Phamarcy. 2018; 13 (2).
8. Cardona V, Ansotegui IJ, Ebisawa M, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020; 13(10): 100472. doi:10.1016/j.waojou.2020.100472.
9. Spataro F, Carlucci P, Loverre T, et al. Hypersensitivity reaction during enzyme replacement therapy in lysosomal storage disorders. A systematic review of desensitization strategies. Pediatr Allergy Immunol. 2023; 34(6): e13981. doi:10.1111/pai.13981.
10. Vultaggio A, Matucci A, Nencini F, et al. Mechanisms of Drug Desensitization: Not Only Mast Cells. Front Pharmacol. 2020;11:590991. Published 2020 Dec 23. doi:10.3389/fphar.2020.590991.
11. Reusser P, Einsele H, Lee J, et al. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. Blood. 2002; 99(4): 1159-1164. doi:10.1182/blood.v99.4.1159.